

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
red to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/086,145
Filing Date	October 19, 2001
First Named Inventor	Pairet, M. et al
Art Unit	1614
Examiner Name	To be Assigned
Attorney Docket Number	1/1174

U.S. PATENT DOCUMENTS

[illegible]

RECEIVED

JUN 21 2002

TECH CENTER 1600/2900

**COPY OF PAPERS
ORIGINALLY FILED**

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code 3 - Number 4 - Kind Code 5 (if known)				
		EP05040112 A2	05/03/1992	Ciba-Geigy AG		
		DE 198 35 346 A1	05/08/1998	Boehringer Ingelheim Pharma KG	No translation has been provided.	

- No translation
has been
provided.

Examiner
Signature


Date
Considered

11/15/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

Complete if Known

Application Number	10/086,145
Filing Date	October 19, 2001
First Named Inventor	Pairat, M. et al
Group Art Unit	1614
Examiner Name	To be Assigned
Attorney Docket Number	1/1174

RECEIVED

JUN 1 2002

TECH CENTER 1600/29C

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
N/D		F. MON, et al; Aerosol Therapy in Asthma, Revue Des Maladies Respiratoires, Bd. 6, Nr. 3, 1989 Seiten 189-200 - XP001078722	
		G. BLAZANO, et al, Effectiveness and Acceptability of a Domiciliary Multidrug Inhalation Treatment in Elderly Patients with Chronic Airflow Obstruction: Metered Dose Inhaler Versus Jet Nebulizer, Journal of Aerosol Medicine, Vol. 13, No. 1, 2000, PP 25-33	
		RUTGERS, STEVEN R., et al; Short-term Treatment with Budesonide Does Not Improve Hyperresponsiveness to Adenosine 5- Monophosphate in COPD, American Journal of Respiratory and Critical Care Medicine, Vol. 157, pp 880-887	
		CONSTANT P. van SCHAYCK, et al; Periodic Treatment Regimens with Inhaled Steroids in Asthma or Chronic Obstructive Pulmonary Disease, Journal of American Medical Association, July 12, 1995, Vol. 274, No. 2, pp 161-164	
		DEMETRI PAVIA, et al; Preliminary Data from Phase II Studies with RespiMat, a Propellant-Free Soft Mist Inhaler, Journal of Aerosol Medicine, Vol. 12, Supplement 1, 1999 pp S-33-S-39	
		KOICHI NISHIMURA, et al; Additive effect of oxitropium bromide in combination with inhaled corticosteroids in the treatment of elderly patients with chronic asthma, Allergy International (1999) 48: 85-88, Short Communication XP-001070756	

COPY OF PAPERS
ORIGINALLY FILED

Examiner Signature	<i>[Signature]</i>	Date Considered	11/15/02
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.